PROCAPS GRP S.A. DL -01
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more
PROCAPS GRP S.A. DL -01 (9X1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PROCAPS GRP S.A. DL -01 (9X1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PROCAPS GRP S.A. DL -01 - Net Assets Trend (None–None)
This chart illustrates how PROCAPS GRP S.A. DL -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PROCAPS GRP S.A. DL -01 (None–None)
The table below shows the annual net assets of PROCAPS GRP S.A. DL -01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PROCAPS GRP S.A. DL -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PROCAPS GRP S.A. DL -01 Competitors by Market Cap
The table below lists competitors of PROCAPS GRP S.A. DL -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NH Hoteles
MC:NHH
|
$119.44 Million |
|
Jeld-Wen Holding Inc
NYSE:JELD
|
$119.50 Million |
|
Galata Wind Enerji Anonim Sirket
IS:GWIND
|
$119.51 Million |
|
WALLIX GROUP EO -10
F:3WG
|
$119.51 Million |
|
HORIZON FIXTURE GROUP CO LTD
TW:6957
|
$119.43 Million |
|
Merchants' National Properties Inc
PINK:MNPP
|
$119.41 Million |
|
Indigo Acquisition Corp. Ordinary Shares
NASDAQ:INAC
|
$119.41 Million |
|
Eternal Hospitality Group Co.,Ltd.
PINK:TORIF
|
$119.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PROCAPS GRP S.A. DL -01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PROCAPS GRP S.A. DL -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PROCAPS GRP S.A. DL -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PROCAPS GRP S.A. DL -01's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PROCAPS GRP S.A. DL -01 (9X1) | €- | N/A | N/A | $119.43 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |